The transfer of chromosomally 'abnormal' embryos can still result in pregnancy in IVF

July 4, 2017, European Society of Human Reproduction and Embryology

IVF embryos whose cells have mixed chromosomal profiles - one normal, another abnormal - still have the potential to implant in the uterus and become a healthy pregnancy, according to a study presented today at the 33rd Annual Meeting of ESHRE.

This pattern of embryonic mosaicism, which is characterised by the presence of two or more genetically distinct cell lineages, typically one with a chromosome abnormality and the other with a normal chromosome composition, has become a controversial topic in recent months, with debate over their potential viability. In the light of this latest study, which was performed by the GENOMA group and European Hospital IVF Center in Rome, Dr Francesco Fiorentino from the Molecular Genetics Laboratory of GENOMA, who will present today's study, said that its results "confirm that can develop into healthy euploid [chromosomally healthy] newborns".

This possibility was first raised by Dr Fiorentino's group and the European Hospital in a letter to the New England Journal of Medicine in November 2015, which described six healthy deliveries in a small series of 18 women for whom embryo screening had found no chromosomally normal (euploid) embryos.(1) Up to this point mosaic embryos were not usually transferred in IVF because they (like all other aneuploid embryos) were considered abnormal. Even in their NEJM letter, the Rome investigators noted that "it is reasonable to assume that mosaicism reduces the likelihood of success of IVF".

The bottom line of this latest study reported at ESHRE is that success or failure following the transfer of a mosaic embryo in IVF depends on the extent of the mosaicism and chromosomal abnormality (aneuploidy) in the embryo.

The study included 73 women for whom embryo screening following IVF had found no chromosomally normal embryos for transfer. Screening had, however, identified mosaic embryos in each of these patients, which were then offered for transfer. For the purpose of the study and assessment of development potential, these mosaic embryos were classified as having low (<50%) or high (>50%) degrees of aneuploidy.

Results of the study showed that pregnancy and delivery were indeed possible following the transfer of mosaic embryos. However, the transfers of mosaic embryos with a high percentage of chromosomally abnormal cells (>50%) resulted in a live birth rate of 16.7%, with a miscarriage rate of 10%. In contrast, mosaic embryos with a lower aneuploidy percentage (<50%) resulted in a higher live birth rate of 39.5%, with miscarriage occurring in just 7.0% of the transfers. The difference between the two delivery rates was statistically significant, suggesting, said Dr Fiorentino, that "priority for transfer should be given to mosaic embryos with low levels of aneuploidy".

Dr Fiorentino said there are several reasons why an embryo with clearly detectable levels of aneuploidy might self-correct and develop into a healthy newborn. One reason, he explained, may be related to the fact that the aneuploid cells have a growth disadvantage or are simply eliminated by processes such as apoptosis. This may lead to a decline in number as the embryo develops, ultimately resulting in a normal fetus.

However, he added that mosaic embryos may now be considered a "distinct category" in terms of potential to implant and develop, lying somewhere between euploid and fully aneuploid embryos. "Euploid embryos have a higher implantation potential than mosaic embryos," said Dr Fiorentino, "and because of this we suggest that mosaic embryos should only be transferred in women with no euploid embryos available. The transfer of euploid embryos, when available, results in higher implantation rates and a lower risk of miscarriage, and represents the preferred option for IVF patients."

Dr Fiorentino added that this finding - that mosaic embryos have the potential for implantation and pregnancy and may influence the clinical outcome of IVF - now suggests that all women may benefit from aneuploidy testing before embryo .

Explore further: The more eggs the better in IVF?

More information: Abstract O-182, Tuesday 4 July 2017: The extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments

Related Stories

The more eggs the better in IVF?

July 3, 2017
A higher number of eggs retrieved in an IVF treatment cycle is independently associated with more chromosomally normal embryos available for transfer, according to a new Australian study. However, the benefit of a greater ...

Controversial fertility treatment resulted in live births

November 18, 2015
(HealthDay)—Embryos with a mix of normal and abnormal chromosomes implanted during in vitro fertilization (IVF) can develop into healthy newborns, a small new study suggests.

Mitochondrial DNA levels as a marker of embryo viability in IVF

July 4, 2016
Despite the claims and counter-claims for new embryo assessment techniques introduced over the past two decades, the search for the holy grail of assisted reproduction - the key to the embryo destined to implant - continues. ...

Screening for genetic diseases & chromosomal defects with a single biopsy improves pregnancy rates

June 13, 2017
Couples who are undergoing pre-implantation genetic diagnosis (PGD) in order to avoid transmission of inherited diseases, such as Duchenne muscular dystrophy or cystic fibrosis, should also have their embryos screened for ...

Solving the mystery of defective embryos

January 4, 2016
It's the dream of many infertile couples: to have a baby. Tens of thousands of children are born by in vitro fertilization, or IVF, a technique commonly used when nature doesn't take its course. However, embryos obtained ...

Technology to screen embryos before implantation falls short

March 31, 2017
The healthy development of an embryo created through in vitro fertilization (IVF) depends on whether most, if not all, of the cells have the proper number of chromosomes. With pre-implantation genetic screening (PGS) technology, ...

Recommended for you

New study reveals time and day women are most likely to give birth

June 15, 2018
A new study has found that the time and day that women give birth can vary significantly depending on how labour starts and the mode of giving birth.

Blood test for pregnant women can predict premature birth

June 7, 2018
A new blood test for pregnant women detects with 75-80 percent accuracy whether their pregnancies will end in premature birth. The technique can also be used to estimate a fetus's gestational age—or the mother's due date—as ...

Drug combination offers more effective care for patients suffering miscarriage

June 6, 2018
A combination of the drugs mifepristone and misoprostol can help bring closure to some women and their families suffering from miscarriage, and reduces the need for surgical intervention to complete the painful miscarriage ...

Genes, environment and schizophrenia—new study finds the placenta is the missing link

May 28, 2018
Hiding in plain sight, new research shines a spotlight on the placenta's critical role in the nature versus nurture debate and how it confers risk for schizophrenia and likely other neurodevelopmental disorders including ...

Vendors say pot eases morning sickness. Will baby pay a price?

May 22, 2018
(HealthDay)—Nearly 70 percent of Colorado marijuana dispensaries recommended pot products to manage early pregnancy-related morning sickness, new research reveals.

Pregnancy drug DES might have triggered ADHD in the grandchildren of women who used it

May 21, 2018
A study conducted by researchers at Columbia University's Mailman School of Public Health and Harvard T.H. Chan School of Public Health reported elevated odds for attention deficit hyperactivity disorder (ADHD) in the grandchildren ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.